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Abstract
Background
Individuals diagnosed with neurocysticercosis often present with epilepsy and sometimes
with progressively worsening severe chronic headaches (WSCH). While cross-sectional
associations between seropositivity to cysticercal antigens and epilepsy have been
reported, few large scale studies have been conducted in West Africa and none have mea-
sured the association between seropositivity to cysticercal antigens and headaches. This
study aimed at filling these knowledge gaps by estimating the strength of the cross-sectional
association between seropositivity to cysticercal antigens and the prevalence of epilepsy
and WSCH in 60 villages of Burkina Faso, West Africa.
Methodology/Principal findings
Baseline data from a cluster randomized controlled trial collected from January 2011 to Feb-
ruary 2012 in 60 villages across three provinces in Burkina Faso were used. Between 78
and 80 individuals were screened for epilepsy and WSCH in each village, and those
screened positive were confirmed by a physician. Seventy-five percent of all participants
were asked to provide a blood sample to test for Taenia solium cysticercus circulating anti-
gens. Hierarchical multivariable logistic models were used to measure the association
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between seropositivity to cysticercal antigens and epilepsy (lifetime and active) as well as
WSCH. Among 3696 individuals who provided a blood sample, 145 were found to have epi-
lepsy only, 140 WSCH only and 19 both. There were positive associations between sero-
positivity to cysticercal antigens and active epilepsy (prevalence odds ratio (POR): 2.40
(95%CI: 1.15–5.00)) and WSCH (POR: 2.59 (1.34–4.99)).
Conclusions/Significance
Our study is the first to demonstrate a cross-sectional association between seropositivity to
cysticercal antigens and WSCH in a large community-based study conducted in West
Africa. The measured cross-sectional association had a strength similar to the ones previ-
ously observed between seropositivity to cysticercal antigens and lifetime or active epilepsy.
As a result, preventing new cysticercosis cases in communities may reduce the prevalence
of these two important neurological disorders.
Author summary
Taenia solium is a parasite that can be transmitted between humans and pigs in areas with
poor sanitation and pig management practices. When this parasite infects the human
brain, it can cause epilepsy or severe headaches. Our study aimed to measure the associa-
tion between being seropositive to cysticercal antigens and having epilepsy (lifetime and
active) or severe headaches in 60 villages of Burkina Faso. We found that active epilepsy
and severe headaches were associated with seropositivity to cysticercal antigens. These
results confirm prior studies which suggested an association between being seropositive
for cysticercal antigens and these two neurological symptoms. Preventing cysticercosis
could reduce new cases of these two neurological symptoms from occurring.
Introduction
Epilepsy is reported to disproportionately affect rural low income countries [1], with lifetime
epilepsy estimated to being nearly three times higher in rural developing countries compared
to developed countries [1]. The prevalence of epilepsy is also reported to vary within sub-Saha-
ran Africa (SSA) [2], potentially due to the distribution of risk factors across populations as
well as variable impacts of selection and misclassification error biases in the published litera-
ture [2–4].
The prevalence of active headache disorders, in contrast to epilepsy, has consistently been
reported to be the highest in high income countries [5]. In a review of 107 studies, the preva-
lence of current migraine was found to be highest in Europe at 15% and lowest in Africa at 5%,
but the latter estimate was based on only seven studies [5]. Four community-based prevalence
studies from SSA have reported one-year prevalence estimates for migraines and tension-type
headaches ranging from 3.0% to 5.4% and 1.7% to 7.0%, respectively [6–9].
Neurocysticercosis (NCC) is suspected to play a role in the elevated prevalence of epilepsy
in some low income countries [10]. NCC results from infection of the central nervous system
with the larval stage of the tapeworm Taenia solium [11,12]. When humans or pigs harbor the
larval stage of T. solium, the infection is referred to as human cysticercosis or porcine cysticer-
cosis, respectively [13]. Human cysticercosis is acquired by ingesting T. solium eggs excreted
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in the feces of a human carrier of the adult cestode (i.e. taeniosis cases) [14]. Epilepsy and pro-
gressively worsening severe chronic headaches (WSCH) were shown in a meta-analysis to be
the two most commonly reported neurological clinical manifestations among individuals with
a diagnosis of NCC [15].
Two meta-analyses suggested that seropositivity to circulating antigens (current infection)
or antibodies of cysticercosis (previous or current exposure to infection) were associated with
epilepsy [16,17]. These meta-analyses demonstrated very limited evidence on the association
between seropositivity to cysticercal antigens and epilepsy in community-based studies.
Indeed, of the 38 unique studies included in these two meta-analyses, three used a combina-
tion of tests to detect seropositivity to cysticercal antigens and antibodies while only two
focused on the association between seropositivity to cysticercal antigens and epilepsy [16,17].
Of those, three studies found a positive association, including the two studies that examined
the association between seropositivity to cysticercal antigens only and epilepsy, but the small
sample sizes resulted in wide confidence intervals [18–20]. Therefore, more studies with larger
sample sizes evaluating the association between seropositivity to cysticercal antigens and epi-
lepsy are needed.
The association between seropositivity to cysticercal antigens or antibodies, and headaches
is even less studied. Only one community-based study conducted in Ecuador is available,
which reported a prevalence odds ratio (POR) of 3.1 (95% CI: 1.1–8.5) between seropositivity
to cysticercal antibodies and migraines [21]. A similar POR was found between the presence of
intra-parenchymal NCC lesions and migraines [21]. No NCC lesions were found among those
with tension-type headaches. In a more recent study, intraparenchymal calcified lesions of
NCC were found to be associated with lifetime prevalence of headaches and intense headaches
[22]. Hence, there is growing evidence of a possible association between cysticercosis and
headaches, but no study has investigated the association between seropositivity to cysticercal
antigens and headaches.
The aim of this paper is to examine whether the presence of T. solium cysticercus circulat-
ing antigens is associated with the prevalence of epilepsy and WSCH in a large community-
based study conducted in 60 villages across three provinces in Burkina Faso. These results will
help determine whether cysticercosis is a potential modifiable risk factor for epilepsy and
WSCH.
Methods
Research design
This study is a prevalence case-control study of epilepsy and WSCH using the baseline cross-sec-
tional component of a cluster randomized controlled trial aimed at estimating the effectiveness of
an educational intervention to reduce the incidence of cysticercosis in humans [23]. The baseline
participant recruitment and data collection took place from February 2011 to January 2012.
Study sample
The aim of the sampling strategy was to screen 80 individuals for epilepsy and WSCH in each
village, of whom 60 would provide a blood sample for the detection of circulating cysticercal
antigens. One person per concession—a compound consisting of a chief and one to several
households—was sampled, resulting in up to 80 individuals in 80 concessions sampled per vil-
lage. The study took place in 60 villages across three provinces. Details on villages and conces-
sions’ selection are provided elsewhere [24,25]. Briefly, 60 eligible villages located in 30
administrative departments were selected for future block randomization of the intervention
[23].
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Selection of participants
In each selected concession, the chief was asked for consent and to enumerate all households,
of which one was randomly selected. The selected household head was asked for his or her
consent and to list all members older than 5 years of age living in the household along with
information on which members had epilepsy. One household member was randomly selected
and asked for consent. The first 60 consenting individuals were asked to provide a blood sam-
ple and to answer a screening questionnaire. If an individual did not consent to give a blood
sample, he or she was invited to participate in the questionnaire component of the study. Once
60 individuals consented to provide blood samples, all other sampled individuals were invited
to participate in the screening questionnaire only, until a total of up to 80 participants were
enrolled in each village. All participants confirmed as having epilepsy or WSCH were also
asked to provide a blood sample. Few refused to participate in the serological component of
the study and all agreed to participate in the screening questionnaire component.
Measurement and definition of epilepsy and severe chronic headaches
A screening questionnaire for epileptic seizures, epilepsy and WSCH was administered to all
participants. The part of the questionnaire concerning epilepsy was based on the International
League Against Epilepsy (ILAE) screening of epilepsy questionnaire developed by Preux et al.
[26], and had been used by this research group in Burkina Faso in three villages in prior studies
[18,27]. The questionnaire was further adapted to capture NCC-related headaches [28]. Indi-
viduals that screened positive were invited to be evaluated by a study physician, trained by a
neurologist, for confirmation. In addition, 231 individuals screened negative were randomly
selected to be examined by the physician in 37 villages. All physicians’ diagnoses were reviewed
by the study neurologist. All confirmed cases of epilepsy and WSCH were invited to have a
CT-scan, but results of this test will be reported elsewhere.
The primary outcomes of this study were neurologist-confirmed epilepsy and WSCH. Epi-
lepsy was defined as more than one seizure of central nervous system origin without apparent
cause in a lifetime [29]. Active epilepsy was defined as having had a seizure within the preced-
ing five years, to allow for comparison across studies [19,30]. Individuals that did not meet the
case definition of epilepsy were considered as epilepsy-free [31]. Six individuals diagnosed
with single seizure only were excluded from all analyses. WSCH were defined as symptoms
currently occurring more than once a week for more than two weeks, with each episode lasting
for at least 3 hours and with a pain intensity that affected the ability to work, play, attend
school or carry out usual activities or that requires analgesics [32]. Headaches also had to be
progressively worsening in severity. This definition of WSCH was based on the headache defi-
nition by Jensen and Stovner [33] and adapted to capture characteristics specific to NCC [28].
Measurement and definition of the primary exposure
The primary exposure was the presence of circulating cysticercal antigens in the blood as an
indicator of the presence of viable cysticerci. The presence of circulating cysticercal antigens in
the serum was measured using the B158/B60 enzyme-linked immunosorbent assay (Ag-
ELISA) [34,35]. In a study conducted in Ecuador, this test was reported to have a sensitivity of
90% (95%BCI: 80–99%) and a specificity of 98% (95%BCI: 97–99%) to detect current cysticer-
cosis [36]. In people with epilepsy, this test was reported to have sensitivities of 100% (95%CI:
54–100%) and 28% (95%CI: 13–47%) to detect active and inactive NCC lesions, respectively,
while the specificity was estimated to be 83% (95% CI: 70–93%) for both[34]. Blood samples
were collected by venipuncture and placed in 10 ml Venosafe serum gel tubes. Each sample
was tested in duplicate wells of the ELISA. The mean Optical Density (OD) for each sample
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was obtained from the duplicate wells, which was then divided by a cut-off OD value to obtain
a ratio. The cut-off OD was determined from a Student’s-t distribution with 7 degrees of free-
dom and a type I error of 0.001 using the mean and variance OD of eight negative control sera.
The sample was considered seropositive for cysticercal antigens if the ratio was greater than 1
[37].
Measurement of potential confounders and effect modifiers
The screening questionnaire gathered information on age, gender, ever attending school,
occupation, pork consumption behavior, and history and knowledge of infection with the
adult form of T. solium. The senior woman of the selected individual’s household was inter-
viewed to gather information on pork preparation and consumption, and household members’
latrine use and access. The number of individuals identified by the chief of the household as
having epilepsy was used as a proxy for measuring genetic epilepsy.
Statistical methods
We first conducted descriptive analyses of the study population characteristics and of each out-
come. In all models, individuals screening negative among those not seen by a physician and
without confirmed epilepsy and WSCH among those seen by a physician were considered as
not having the outcome of interest. We then estimated the crude associations between these
characteristics and the prevalence of lifetime epilepsy, active epilepsy and WSCH using hierar-
chical logistic regression models with village-level and province-level random-effect intercepts.
To account for the sampling design, all models adjusted for the type of concession sampled
(see [24] for details).
To assess the relationship between seropositivity to cysticercal antigens and the two out-
comes of interest while adjusting for confounding, we developed directed acyclic graphs
(DAGs) with DAGitty [38] based on a priori knowledge. We considered the reported age, pre-
vious school attendance, gender, occupation, pork consumption, and latrine access reported
by the mother as potential confounding variables. Using the DAGS, we determined the mini-
mal set to adjust for confounding and measure the unbiased association between seropositivity
to cysticercal antigens and both outcomes were: age, gender and whether the individual had
ever attended school. In the model for epilepsy, we also adjusted for whether the individual
came from a household with more than one individual with epilepsy. Age was categorized into
three groups as 6–17 years, 18–40 years and 41 years and above.
Risk factors identified as associated with seropositivity to cysticercal antigens in Carabin
et al., 2015 [25] were used to impute the values of missing Ag-ELISA results. The results of the
models with and without imputed data for Ag-ELISA were similar, therefore we only present
results without imputed data.
For the multivariable models, hierarchical logistic regression models were used to measure
the association between seropositivity to cysticercal antigens and lifetime epilepsy, active epi-
lepsy and WSCH adjusted for the confounding variables. We reported the POR and the associ-
ated confidence interval (95%CI).
All analyses were conducted with Stata 14.
Ethical review
This study was approved by the Institutional Review Board at the University of Oklahoma
Health Sciences Center and the ethical review panel at the Centre MURAZ (Burkina Faso). All
participants were given written consent forms that were read by the field staff. Consent forms
were signed or marked with an X or a fingerprint by those who were unable to write. All
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consent forms were signed by a witness. For those less than 16 years of age but 5 or greater,
parents gave consent for their children. Assent was given by individuals aged 10 to 15 years.
The field staff answered participants’ questions. As an incentive to participate in the study, all
participants were given a bar of soap.
Results
A total of 4794 participants consented to the questionnaire component of the study, 4775
answered all the screening questions among whom 3708 provided a blood sample for the
detection of circulating cysticercal antigens. Six of the samples could not be analyzed due to
small volume of serum available and an additional six with single seizures only were excluded,
leaving 3696 individuals for the analysis (Fig 1).
A total of 614 individuals screened positive for epilepsy, WSCH or both, among whom 583
(95.0%) were examined by a medical doctor to confirm their diagnosis. Among those screened
negative for epilepsy and WSCH, 201 were randomly selected for examination by a medical
doctor to confirm their diagnosis.
Table 1 shows the characteristics of the study population. There were 145, 140 and 19 indi-
viduals diagnosed as having lifelong epilepsy, WSCH and both, respectively. These included 9,
16 and 2 individuals with confirmed lifetime epilepsy, WSCH and both, respectively, from
individuals who had initially screened negative. Of the 164 people diagnosed with lifelong epi-
lepsy, 125 (76.2%) had active epilepsy. The proportion of seropositivity to cysticercal antigens
was 3.4% in the entire study population. There was a high proportion of individuals that had
never attended school (70.4%) and did not have access to a latrine (87.9%). A small proportion
of household chiefs reported that more than one person had epilepsy in their household
(0.7%).
There were 11 (6.7%), 12 (7.6%) and 106 (3.1%) individuals who were seropositive to cysti-
cercal antigens among those with confirmed lifetime epilepsy, WSCH and without confirmed
epilepsy or WSCH, respectively. Table 2 shows the POR of lifetime and active epilepsy as well
as of WSCH associated with seropositivity to cysticercal antigens from the univariable and
Fig 1. Flow chart of the study sample across 60 villages in three provinces of Burkina Faso, 2011–2012.
https://doi.org/10.1371/journal.pntd.0007101.g001
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Table 1. Characteristics of 3696 individuals in the study population across 60 villages in rural Burkina Faso, Feb-
ruary 2011-January 2012.
Variable Characteristic N (%)
Confirmed neurological diagnosis Lifetime epilepsy 164 (4.4%)a
Active epilepsy 125 (3.4%)
WSCHb 159 (4.3%)
None 3392
(91.8%)
Seropositivity to cysticercal antigens Negative 3569
(96.6%)
Positive 127 (3.4%)
Province Boulkiemde 1834
(49.6%)
Nayala 599
(16.2%)
Sanguie 1263
(34.2%)
Age (16 missing) 6–17 years 1180
(32.1%)
18–40 years 1281
(34.8%)
41 years and older 1219
(33.1%)
Gender (1 missing) Female 2033
(55.0%)
Male 1662
(45.0%)
Have you ever attended school? (1 missing) No 2602
(70.4%)
Yes 1093
(29.6%)
Occupation (1 missing) Student/Pupil 726
(19.7%)
Farmer/gardener 1377
(37.3%)
Housewife/house cleaner 1320
(35.7%)
Commerce/ Salaried/ Skilled self-employed/
Unemployed
272 (7.4%)
Access to a latrine (28 missing) No 3223
(87.9%)
Yes 445
(12.1%)
Where do you eat pork? (3 missing) Never ate pork 896
(24.3%)
Eat pork at home only 1256
(34.0%)
Eat pork in other home 429
(11.6%)
Eat pork at the village market 596
(16.1%)
Eat pork in another village market 215 (5.8%)
Ate pork before, not now 301 (8.2%)
(Continued)
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multivariable hierarchical logistic models. In the univariable models, seropositivity to cysticer-
cal antigens was associated with lifetime epilepsy (POR: 2.19 (95%CI: 1.14–4.19), active epi-
lepsy (POR: 2.65 (95%CI: 1.34–5.23) and WSCH (POR: 2.68 (95%CI: 1.42–5.03)). In the
multivariable models adjusted for the minimal set of confounders identified with the DAGs,
the association between seropositivity to cysticercal antigens and active epilepsy (POR: 2.40
(95%CI: 1.15–5.00) and WSCH (POR: 2.59 (1.34–4.99)) decreased but remained statistically
significant while the strength of the association for lifetime epilepsy became statistically non-
significant (POR: 1.89 (95%CI: 0.94–3.79)). For lifetime and active epilepsy, adjustment for the
minimal set has to be interpreted with care because, empirically, age, gender and school atten-
dance were not associated with lifetime and active epilepsy among those seronegative to cysti-
cercal antigens (i.e. the unexposed), making these variables non confounding variables in our
dataset. A model only adjusting for the presence of more than one person with epilepsy in the
household resulted in a POR of 2.18 (95%CI: 1.13–4.21) for lifetime epilepsy and 2.63 (95%CI:
1.32–5.26) for active epilepsy.
The strength of the associations between the socio-demographic variables explored and life-
time epilepsy, active epilepsy and WSCH are presented in Table 2. For the variables identified
as being part of the minimal adjustment set in the DAGs, being an adult (18–40 years, and 41
years and above compared to 6–17 years), a woman and attending school showed statistically
significant associations with WSCH but not lifetime or active epilepsy in the univariable hier-
archical logistic models. Living in a household with more than one person with epilepsy was
associated with higher prevalence odds of lifetime and active epilepsy compared to those who
do not in the univariable models. In the multivariable models assessing the association
between seropositivity to cysticercal antigens and lifetime and active epilepsy, only the effect of
having more than one person with epilepsy was statistically significant. The effect of older age
groups and being a female remained statistically significant in the multivariable model for
WSCH, but school attendance became statistically non-significant, primarily due to the con-
founding effect of age and gender.
Of the other variables explored but not part of the minimal set in the multivariable models,
individuals with an occupation other than being a pupil had a higher prevalence odds of
WSCH and of lifetime epilepsy, but this was confounded by age. Declaring having eaten pork
in the past but not anymore was associated with higher prevalence odds of both epilepsy and
WSCH compared to those declaring never having eaten pork. Declaring eating pork at home
only, in another home and at the village market was associated with higher prevalence odds of
lifetime and active epilepsy, compared to those declaring never having eaten pork.
Table 1. (Continued)
Variable Characteristic N (%)
Have more than one household member with
epilepsy? (20 missing)
No 3652
(99.3%)
Yes 24 (0.7%)
Type of concession Sow 500
(13.5%)
Piglet 1395
(37.4%)
Any type of concession 1801
(48.7%)
a Includes the 125 individuals with active epilepsy and 19 individuals with both epilepsy and WSCH.
b Includes the 19 individuals with both epilepsy and WSCH.
https://doi.org/10.1371/journal.pntd.0007101.t001
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Table 2. Distribution of socio-demographic characteristics according to the neurological outcome and the associated prevalence odds ratios (POR) (95%CI) for life-
time epilepsy, active epilepsy and progressively worsening severe chronic headaches (WSCH) from univariable and multivariable hierarchical logistic models in
3696 individuals across 60 villages in rural Burkina Faso, February 2011-January 2012.
No confirmed
neurological
outcome
Lifetime epilepsy Active epilepsy WSCH
Characteristic N (%) N (%) Crude
POR (95%
CI)
Adjusted
PORa (95%
CI)
N (%) Crude
POR (95%
CI)
Adjusted
PORa (95%
CI)
N (%) Crude
POR (95%
CI)
Adjusted
PORb (95%
CI)
Seropositive to
cysticercal antigens
Negative 3286 (96.9%) 153
(93.3%)
Reference Reference 115
(92.0%)
Reference Reference 147
(92.5%)
Reference Reference
Positive 106 (3.1%) 11
(6.7%)
2.19 (1.14;
4.19)
1.89 (0.94;
3.79)
10
(8.0%)
2.65 (1.34;
5.23)
2.40 (1.15;
5.00)
12
(7.6%)
2.68 (1.42;
5.03)
2.59 (1.34;
4.99)
Age (16 missing) 6–17 years 1120 (33.2%) 49
(30.3%)
Reference Reference 37
(30.1%)
Reference Reference 11
(7.0%)
Reference Reference
18–40 years 1172 (34.7%) 57
(35.2%)
1.15 (0.78;
1.71)
1.09 (0.72;
1.66)
49
(39.8%)
1.31 (0.84;
2.03)
1.20 (0.75;
1.92)
60
(38.0%)
5.24 (2.73–
10.03)�
5.26 (2.67;
10.36)�
41 years and
older
1087 (32.2%) 56
(34.6%)
1.25 (0.84;
1.86)
1.04 (0.66;
1.64)
37
(30.1%)
1.06 (0.66;
1.69)
0.83 (0.49;
1.40)
87
(55.1%)
8.73 (4.62–
16.52)�
10.08 (5.03;
20.17)�
Gender (1 missing) Female 1845 (54.4%) 85
(51.8%)
Reference Reference 65
(52.0%)
Reference Reference 118
(74.2%)
Reference Reference
Male 1546 (45.6%) 79
(48.2%)
1.09 (0.80;
1.50)
1.11 (0.80;
1.54)
60
(48.0%)
1.09 (0.76;
1.56)
1.14 (0.78;
1.66)
41
(25.8%)
0.41 (0.29;
0.59)
0.39 (0.27;
0.57)�
Have you ever
attended school (1
missing)
No 2366 (69.8%) 123
(75.0%)
Reference Reference 93
(74.4%)
Reference Reference 128
(80.5%)
Reference Reference
Yes 1025 (30.2%) 41
(25.0%)
0.77 (0.54;
1.11)
0.72 (0.47;
1.10)
32
(25.6%)
0.78 (0.52;
1.18)
0.71 (0.44;
1.13)
31
(19.5%)
0.55 (0.37–
0.83)�
1.42 (0.90;
2.23)
Type of concession Sow 455 (14.4%) 27
(16.5%)
Reference Reference 20
(16.0%)
Reference Reference 20
(12.6%)
Reference Reference
Piglet 1268 (37.4%) 72
(43.9%)
0.95 (0.60;
1.49)
0.92 (0.58;
1.46)
55
(44.0%)
0.98 (0.58;
1.66)
0.95 (0.56;
1.62)
61
(38.3%)
1.09 (0.65;
1.83)
1.04 (0.61;
1.76)
Any 1669 (49.2%) 65
(39.6%)
0.66 (0.41;
1.05)
0.62 (0.39;
1.00)�
50
(40.0%)
0.69 (0.42;
1.17)
0.64 (0.38;
1.11)
78
(49.1%)
1.07 (0.64;
1.77)
1.03 (0.62;
1.73)
More than 1
household member
with epilepsy (20
missing)
No 3359 (99.6%) 155
(94.5%)
Reference Reference 118
(94.4%)
Reference Reference NA��� NA��� NA���
Yes 14 (0.4%) 9
(5.5%)
12.99
(5.45;
30.97)�
15.02 (6.21;
36.36)�
7
(5.6%)
12.73
(5.00;
32.4)�
15.44 (6.01;
39.65)�
NA��� NA��� NA���
Occupation (1
missing)
Student/ pupil 698 (20.6%) 20
(12.2%)
Reference NI�� 16
(12.8%)
Reference NI�� 8
(5.0%)
Reference NI��
Farmer /
gardener
1259 (37.1%) 72
(43.9%)
1.99 (1.20;
3.30)�
NI�� 50
(40.0%)
1.75 (0.99;
3.10)
NI�� 53
(33.3%)
3.57 (1.68;
7.57)�
NI��
Housewife /
house cleaner
1197 (35.3%) 46
(28.1%)
1.39 (0.81;
2.37)
NI�� 37
(29.6%)
1.40 (0.77;
2.54)
NI�� 86
(54.1%)
6.40 (3.07;
13.32)�
NI��
Commerce /
salaried /
skilled self-
employee
237 (7.0%) 26
(15.9%)
3.97 (2.16;
7.27)�
NI�� 22
(17.6%)
4.15 (2.14;
8.07)�
NI�� 12
(7.6%)
4.79 (1.92;
11.94)�
NI��
Access to a latrine
(28 missing)
No 2958 (87.9%) 142
(87.1%)
Reference NI�� 107
(86.3%)
Reference NI�� 138
(86.8%)
Reference NI��
Yes 407 (12.1%) 21
(12.9%)
1.14 (0.71;
1.84)
NI�� 17
(13.7%)
1.23 (0.72;
2.08)
NI�� 21
(13.2%)
1.11 (0.67;
1.84)
NI��
(Continued)
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Discussion
To our knowledge, this is the first study to examine the association between seropositivity to
cysticercal antigens and two neurological disorders, epilepsy and WSCH, in a large commu-
nity-based study in Sub-Saharan Africa.
Our study found a positive association between seropositivity to cysticercal antigens and
epilepsy in the univariable hierarchical model. However, the strength of the association was
weaker, albeit within the range, of that found in prevalence case-control studies conducted in
three villages of Burkina Faso (POR = 3.4 (95%CI: 1.1–8.9)) and in one division of Burundi
(POR = 3.8 (95%CI: 2.7–5.1)) [18,19]. Our estimate was however stronger than the association
between the presence of antibodies to cysticercosis and epilepsy found in a prevalence case-
control study conducted in Cameroon (OR: 1.3 ((95%CI: 0.6–3.0)) [19,39].
Unlike what was reported in two studies conducted in SSA [18,19], the strength of the asso-
ciation between seropositivity to cysticercal antigens and lifetime epilepsy became statistically
non-significant in a model adjusting for the minimal set of confounding variables identified in
the DAG. This decrease in the magnitude of the association might be partly due to our data
since we did not observe a statistically significant association between gender, age and school
attendance and the outcome among the non-exposed subjects, making this analysis possibly
biased through over-adjustment [40]. However, the association remained significant for active
epilepsy. The association between seropositivity to cysticercal antigens and active epilepsy,
though previously reported, is somewhat counterintuitive since circulating antigens are typi-
cally detected when cysts are viable [13,34] while most NCC-associated seizures are believed to
occur when cysts start degenerating [13]. However, NCC-associated seizures may also be the
result of inflammation around cysts at the vesicular stage, especially in the case of massive
Table 2. (Continued)
No confirmed
neurological
outcome
Lifetime epilepsy Active epilepsy WSCH
Characteristic N (%) N (%) Crude
POR (95%
CI)
Adjusted
PORa (95%
CI)
N (%) Crude
POR (95%
CI)
Adjusted
PORa (95%
CI)
N (%) Crude
POR (95%
CI)
Adjusted
PORb (95%
CI)
Where pork
consumption takes
place (3 missing)
Never ate pork 820 (24.2%) 44
(26.8%)
Reference NI�� 34
(27.2%)
Reference NI�� 36
(22.6%)
Reference NI��
At home only 1191 (35.1%) 26
(15.9%)
0.36 (0.22;
0,60)�
NI�� 20
(16.0%)
0.30 (0.16;
0.54)�
NI�� 42
(26.4%)
0.77 (0.48;
1.24)
NI��
In other home 399 (11.8%) 10
(6.1%)
0.38 (0.18;
0.77)�
NI�� 5
(4.0%)
0.21 (0.08;
0.55)�
NI�� 23
(14.5%)
1.17 (0.66;
2.07)
NI��
At the village
market
556 (16.4%) 19
(11.6%)
0.57 (0.32;
0.99)�
NI�� 15 (12.
0%)
0.48 (0.25;
0.91)�
NI�� 25
(15.7%)
0.97 (0.57;
1.67)
NI��
At market of
another village
191 (5.6%) 14
(8.5%)
1.13 (0.60;
2.14)
NI�� 6
(4.8%)
0.51 (0.20;
1.27)
NI�� 11
(6.9%)
1.24 (0.60;
2.54)
NI��
Ate pork
before, not
anymore
232 (6.9%) 51
(31.1%)
3.58 (2.30;
5.57)�
NI�� 45
(36.0%)
3.60 (2.19;
5.93)�
NI�� 22
(13.8%)
2.15 (1.22;
3.78)�
NI��
aAdjusted for age groups, gender, school attendance, concession type and the number of people with epilepsy in the household as reported by the chief of the household.
bAdjusted for age groups, gender, school attendance and concession type.
� The 95% confidence interval does not include 1.
NI��: Not included
NA���: Not applicable
https://doi.org/10.1371/journal.pntd.0007101.t002
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infections [13]. Moreover, individuals with epilepsy may have had multiple cysts at different
stages, either through re-infection or due to varying speeds at which cysts degenerate.
Our study is the first to report an association between seropositivity to cysticercal antigens
and WSCH. Our prevalence estimate for WSCH was 4.3%. As previously discussed [23], since
we aimed to capture NCC-associated WSCH, our definition of headaches was different from
what had been used in other studies. However, our estimate was slightly higher, but within the
range, to the lifetime migraine prevalence estimate of 3.3% (95%CI: 2.4% –4.6%) in Benin [41],
and lower than the lifetime migraine prevalence estimate of 5.3% (95%CI: 5.0%– 5.6%) in
Nigeria [42]. Only one prior study explored the association between seropositivity to cysticer-
cosis antibodies, using enzyme-linked immunolectrotransfer blot testing, and migraines. In
that cross-sectional study conducted in Ecuador, the POR was estimated at 3.1 (95%CI: 1.1–
8.5) [21]. These results are consistent with our findings although [23] actually examining expo-
sure to cysticercosis instead of seropositivity to cysticercal antigens as measured in our study.
The estimated POR remained very similar in our multivariable model adjusting for con-
founding variables identified with the DAG. In this case, however, age and gender were associ-
ated with the outcome among the unexposed, making these variables confounders in our data.
Headaches might be caused by the presence of cysts in the ventricles or sub-arachnoid space
which is associated with increased intra-cranial pressure or an inflammatory response [13].
Detection of cysticercal antigens in the cerebral spinal fluid or serum has been shown to be
highly sensitive and specific for the detection of subarachnoid NCC [14] and active parenchy-
mal lesions [34]. Our findings might be the result of cysts at different stages of development,
either through re-infection or due to varying speeds at which cysts degenerate, or to extrapar-
enchymal NCC. In addition, a recent matched prevalence case-control study conducted in one
rural Ecuadorian village demonstrated a significant association between calcified NCC (with-
out viable lesions) and lifetime, current and intense headaches [22]. This finding could suggest
that WSCH are the result of infection with less cystic lesions or perhaps “older” active lesions.
It is also be possible that circulating antigens remain in a few cases of calcified NCC, or that
some antigens sporadically released by calcified cysts may be present in the serum of some
cases with calcified NCC [43].
Our study has some limitations. First, the sampling design might have led to selection bias
because concession sampling was based on the presence of pigs. We mitigated the effect of this
bias on the PORs by adjusting for the type of concession in all of our models. Second, seroposi-
tivity to cysticercal antigens was used as a proxy for NCC. Serological tests for circulating cysti-
cercal antigens are not very sensitive for the detection of non-viable parenchymal cysts and
low number of cysts [44]. However, imaging such as CT-scans could only be offered to people
with symptoms, and in the context of Burkina Faso, several people with symptoms refused to
travel to receive imaging for fear of stigmatization. In our study, about 30% of individuals with
confirmed epilepsy or WSCH did not get a CT-scan of the brain to measure NCC. Moreover,
CT-scans are not very sensitive for the detection of live cysts or extraparenchymal cysts [45].
Therefore, seropositivity to cysticercal antigens allowed us to examine the association between
seropositivity to cysticercal antigens and two neurological symptoms in the larger population.
However, the associations observed for epilepsy and WSCH cannot be conclusively attribut-
able to NCC. Third, we did not account for misclassification error of the exposure. We ran
models that accounted for misclassification error for the outcome and did not find it to be an
important bias in our study. Therefore, since our results were similar to other published stud-
ies, misclassification error of the exposure might also not be an important bias. Finally, the
cross-sectional nature of our data did not allow for the assessment of temporality between the
exposure and outcomes. Therefore, individuals with epilepsy and WSCH might have had their
condition due to another cause that occurred prior to cysticercosis. In addition, it is possible
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that people with severe epilepsy are more at risk of acquiring cysticercosis due to increased
exposure to contaminated food or the environment.
Our study also has several strengths. It is the first to report multivariable associations
between seropositivity to cysticercal antigens for both epilepsy and WSCH. The few studies
that examined the association between seropositivity to cysticercal antigens and epilepsy
found a positive association, and we found that the association was very similar for active epi-
lepsy. This study was also conducted in 60 villages and among more than three-thousand indi-
viduals, providing the power to detect associations between an exposure and outcome that
were both relatively rare.
Our study supported the hypothesis that seropositivity to cysticercal antigens is associated
with epilepsy and WSCH. Cohort studies examining sero-conversion to cysticercal antigens
and its association with the development of these two neurological disorders are needed to bet-
ter measure the magnitude of this association in rural communities of SSA.
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